Difference between revisions of "Dasatinib (Sprycel)"
Jump to navigation
Jump to search
m (Text replace - "Category:Tyrosine kinase inhibitors" to "Category:Kinase inhibitors") |
m (→References) |
||
| Line 16: | Line 16: | ||
*[http://chemocare.com/chemotherapy/drug-info/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/dasatinib.aspx Dasatinib (Sprycel) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/dasatinib-patient-drug-information Dasatinib (Sprycel) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *6/28/06: FDA approved for the treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy. | ||
==References== | ==References== | ||
Revision as of 17:01, 6 November 2013
Also known as BMS-354825.
General information
Class/mechanism: Tyrosine kinase inhibitor of BCR-ABL, the SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Binds to multiple conformations of the ABL kinase.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Dasatinib (Sprycel) package insert pages 8-9[1]
- Dasatinib (Sprycel) patient drug information (Chemocare)[4]
- Dasatinib (Sprycel) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/28/06: FDA approved for the treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.